Patheon N.V. (NYSE:PTHN) Files An 8-K Results of Operations and Financial Condition

Patheon N.V. (NYSE:PTHN) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial Condition

On December 20, 2016 Patheon N.V. (the Company) issued a press
release announcing preliminary unaudited financial results for
its fiscal quarter and year ended October 31, 2016. The full text
of the press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K (this Report) and incorporated by reference
into this Item 2.02.
to General Instruction B.2 of Current Report on Form 8-K, the
information in Item 2.02 of this Report, including the press
release attached as Exhibit 99.1, is furnished and shall not be
deemed to be filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section. Furthermore, such information shall
not be deemed to be incorporated by reference into the filings of
the registrant under the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
No.
Description
99.1
Press Release, dated December 20, 2016.


About Patheon N.V. (NYSE:PTHN)

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments are Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment provides manufacturing and packaging for approved prescription, over the counter and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval and beyond, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides development and manufacturing for the biologically active component of a pharmaceutical product from early development through commercial production. It provides a range of active pharmaceutical ingredient and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and life cycle management.

Patheon N.V. (NYSE:PTHN) Recent Trading Information

Patheon N.V. (NYSE:PTHN) closed its last trading session down -0.40 at 28.11 with 701,926 shares trading hands.

An ad to help with our costs